This TikTok about GLP-1s and your brain is actually right

What did @breannekallonen actually say?

Dr. Brianne Callinen, who identifies as a naturopathic and functional medicine doctor, made several distinct claims about GLP-1 receptor agonists. The short version: these drugs don't just suppress appetite, they touch dopamine reward pathways, and some of her patients on long-term or high maintenance doses report what she calls "a flatness" - low motivation, reduced social interest, less excitement. Her proposed solutions are getting to the "minimum effective dose," dialing in nutrition, and something she calls "cyclical dosing," where patients go longer between injections or take temporary breaks to let dopamine responses recover. She frames all of this as clinical observation, not controlled data, and does disclaim it as not medical advice.

To her credit, she is transparent about the limits of what she's saying. These are patient reports, not a study. But 45,000 views means a lot of people are making decisions based on this, so the claims deserve scrutiny.

Does the science back this up?

The dopamine-GLP-1 connection is real and reasonably well-established. The flatness claim is plausible but not proven. GLP-1 receptors are genuinely expressed in dopaminergic brain regions, and there is legitimate research showing these medications affect reward processing beyond appetite.

Work from Erreger et al. and subsequent studies published in journals including Nature Neuroscience and Neuropsychopharmacology have confirmed GLP-1 receptor presence in the ventral tegmental area and nucleus accumbens, regions central to dopamine reward signaling. Blanco-Gandía and colleagues (2021, Neuropharmacology) showed semaglutide reduced alcohol-seeking behavior in rodent models, which maps to her observation about patients losing alcohol cravings. That part is supported.

The "flatness" or anhedonia-adjacent experience she describes is less studied in humans. Case reports and patient forums document it, and a 2023 analysis of GLP-1 adverse event data flagged mood-related signals, but randomized controlled trial data specifically linking maintenance-dose semaglutide to blunted dopamine tone in otherwise healthy adults does not yet exist at scale. Her clinical observation is biologically plausible. It is not confirmed science.

What did they get wrong (or right)?

She gets meaningful credit for the dopamine framing. The mechanism she's describing - GLP-1 acting on mesolimbic reward circuits - is supported by preclinical and early clinical data. The reduction in addictive behaviors like alcohol cravings is not fringe; it's being actively studied in clinical trials.

Where this gets shakier: the "cyclical dosing" recommendation. She presents cycling GLP-1s, meaning extending intervals between doses or taking breaks, as a strategy that "prevents waning long term" and allows dopamine recovery. There is no peer-reviewed evidence supporting this protocol for the purpose she's describing. GLP-1 cycling for weight maintenance is not a validated clinical strategy. The half-life of semaglutide is roughly seven days, meaning gaps in dosing quickly lead to weight regain for most patients, as documented in the STEP 4 withdrawal trial (Rubino et al., 2021, JAMA).

Her plug for her own "reset program" in the middle of a clinical recommendation is worth naming. It's not disqualifying, but listeners should notice when a clinical suggestion and a product pitch arrive in the same breath.

What should you actually know?

The honest answer here is that long-term neurological effects of GLP-1 receptor agonists in humans are genuinely understudied. These drugs became widely used for weight loss only recently, and five-to-ten year neuropsychological outcome data simply does not exist yet. That uncertainty cuts both ways: it means her concern is not crazy, and it means her proposed solution is not validated either.

If you are on a GLP-1 and notice mood changes, reduced motivation, or a flattened emotional baseline, that is worth bringing to your prescribing clinician. It is on the list of things to monitor. What you should not do is self-adjust your dose or attempt "cyclical dosing" without medical supervision, both because of rebound weight gain risk and because these drugs affect cardiovascular and metabolic parameters, not just appetite. Dose decisions belong in a clinical conversation, not a TikTok comment section.

The minimum effective dose principle she mentions is actually reasonable and aligns with how good prescribers think about any chronic medication. That part is worth keeping. The DIY cycling protocol is not.